Patent · US Active

Iridium (III) complexes containing N-heterocyclic carbene ligand, synthesis, and their use thereof in cancer treatment

US11286271B2 · kind B2 · utility

0Cited by

0References

17Claims

0Family size

Assignee

University of Hong Kong · CN

Inventors

Chi-Ming Che · Hong Kong, CN
Tsz Lung Lam · Emmen, CH
Ka Chung Tong · Hong Kong, CN

Key dates

Filing date	Jul 31, 2019
Grant date	Mar 29, 2022
Priority date	—
Expiry date	Jul 31, 2039

Classification

Technology area (CPC A)Human Necessities
CPC primaryA61P35/00
WIPO fieldOrganic fine chemistry
WIPO sectorChemistry

Abstract

Provided herein are Ir(III) complexes comprising N-heterocyclic carbene ligand, method of synthesis of the Ir(III) complexes, a pharmaceutical composition comprises thereof. Also provided herein are the methods for the treatment and prevention of cancer/tumor in patients in need thereof by the administration of the Ir(III) complexes under both dark and light conditions. Also provided is a method of detecting the Ir(III) complex in a biological system. Also provided is a method of making the Ir(III) complex. The Ir(III) complexes possess anticancer activity such as the induction of cell death, inhibition of cellular proliferation, and inhibition of tumor growth in vivo.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.